SCHEMBL6822357

SCHEMBL6822357

COc1ccn2nc(-c3ccccc3F)c(-c3ccc(S(=O)(=O)c4ccccc4)nn3)c2c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
MAPT P10636 1/20 0.35
CRHBP P24387 1/20 0.35
CRHR2 Q13324 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
HTR6 P50406 2/20 0.33
LMNA P02545 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
AURKA O14965 1/20 0.33
MET P08581 1/20 0.33
NR1I2 O75469 1/20 0.32
PDE2A O00408 1/20 0.32
PDE10A Q9Y233 1/20 0.32
POLB P06746 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
IDO1 P14902 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6818747 0.88 AURKA (0.39) MEN1KMT2AHTR6LMNATSHR
SCHEMBL6822095 0.87 MAPK14 (0.39) MAPTSMN1; SMN2MEN1KMT2ALMNA
SCHEMBL6824871 0.77 NPC1 (0.38) NPC1RAB9AMAPTCRHBPCRHR2
SCHEMBL6821911 0.76 PDE3A (0.44) NPC1RAB9AMAPTCRHBPCRHR2
SCHEMBL7367472 0.75 KDM4E (0.39) MEN1KMT2AHTR6LMNATSHR
SCHEMBL6824626 0.75 NPC1 (0.36) NPC1RAB9AMAPTCRHBPCRHR2
SCHEMBL7364009 0.73 LMNA (0.37) NPC1RAB9AMAPTSMN1; SMN2LMNA
SCHEMBL7296061 0.71 IGF1R (0.51) MAPK1
SCHEMBL7373754 0.68 IGF1R (0.39) MAPK1AURKA
SCHEMBL6821442 0.67 HTR6 (0.37) NPC1RAB9AMAPTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof ADRB1, ADRA1D, ADRB3 NPC1 1281/4885RAB9A 1138/4885MAPT 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.